Utilizing prognostic and predictive factors in breast cancer.
In order to make optimal treatment recommendations for patients with early-stage breast cancer, it is essential to accurately determine the patient's underlying risk of disease recurrence and choose a therapy to which the individual is most likely to respond. Lymph node status, tumor size, histopathologic features including tumor type and grade, and hormone receptor status are well-accepted prognostic factors related to breast cancer. In addition, hormone receptor status is a very strong predictor of response to hormonal therapy. However, our currently accepted prognostic and predictive factors fall short and there is a critical need to more accurately identify those most likely to require or benefit from particular therapies. Attention has therefore focused on the determination of novel prognostic and predictive factors. The most promising new factor is the level of urokinase plasminogen activator and its inhibitor plasminogen activator inhibitor. Other putative factors include proliferative rate, the presence of lymphatic or vascular invasion, human epidermal growth factor receptor 2 (HER-2/neu or erbB-2) positivity, the presence of micrometastases in lymph nodes or bone marrow, and gene expression profile by microarray analysis, and by RNA-based methodology. Data regarding potential new prognostic factors are constantly emerging. These studies are frequently challenging to interpret as they are often retrospective, based on relatively small numbers of patients, include a mix of treated and untreated women, and often do not control for other known prognostic factors. Therefore, new data must be interpreted with caution.
Subramaniam
Deepa S
DS
Georgetown University Medical Center, Lombardi Cancer Center, 3800 Reservoir Road, Washington, DC 20007, USA. dss26@gunet.georgetown.edu
Isaacs
Claudine
C
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001707:Biopsy, Needle; D001943:Breast Neoplasms / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology*; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D021701:Sentinel Lymph Node Biopsy; D016019:Survival Analysis
D014408:Biomarkers, Tumor
Ann Surg Oncol. 2004 Mar;11(3 Suppl):227S-30S
15023757
Semin Thromb Hemost. 1991 Jul;17(3):303-12
1796300
Cancer. 1995 Nov 15;76(10):1772-8
8625046
J Clin Oncol. 2003 Sep 15;21(18):3469-78
12972522
J Clin Oncol. 1993 Nov;11(11):2090-100
8229123
J Clin Oncol. 1997 Aug;15(8):2894-904
9256133
J Clin Oncol. 2001 Sep 15;19(18):3808-16
11559718
J Natl Cancer Inst. 1996 Oct 16;88(20):1456-66
8841020
Br J Cancer. 2002 Feb 1;86(3):396-401
11875706
Eur J Cancer. 1994;30A(1):16-22
7908213
CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29
14974761
Cancer. 1988 Aug 1;62(3):531-3
3134120
Lancet. 1999 Jul 17;354(9174):197-202
10421301
J Clin Oncol. 2001 Apr 15;19(8):2334-56
11304787
Breast Cancer Res Treat. 1992;22(3):207-19
1391987
J Natl Cancer Inst. 2000 Dec 20;92(24):1991-8
11121461
Nature. 2002 Jan 31;415(6871):530-6
11823860
Lancet. 1998 May 16;351(9114):1451-67
9605801
Anticancer Res. 2003 Sep-Oct;23(5b):4319-24
14666645
Thromb Haemost. 2004 Mar;91(3):450-6
14983219
J Clin Oncol. 2003 May 15;21(10):1973-9
12743151
N Engl J Med. 2000 Feb 24;342(8):525-33
10684910
Histopathology. 1991 Nov;19(5):403-10
1757079
Clin Biochem. 2004 Jul;37(7):541-8
15234235
Cancer. 1989 Nov 1;64(9):1914-21
2551477
Am J Surg. 2002 Dec;184(6):492-8; discussion 498
12488144
Clin Cancer Res. 2003 Mar;9(3):923-30
12631589
J Clin Oncol. 1995 Mar;13(3):697-704
7884430
J Clin Oncol. 2001 Sep 15;19(18):3817-27
11559719
Breast Cancer Res Treat. 1998;51(3):239-53
10068082
Breast Cancer Res Treat. 1998;52(1-3):227-37
10066085
J Clin Oncol. 1988 Jul;6(7):1076-87
2856862
J Clin Oncol. 1992 Jul;10(7):1044-8
1351537
J Natl Cancer Inst. 2002 Jan 16;94(2):116-28
11792750
Int J Cancer. 1996 Apr 22;69(2):135-41
8608982
J Clin Oncol. 1992 May;10(5):696-705
1569442
J Pathol. 1999 Jan;187(2):207-16
10365096
Cancer. 1980 Jun 15;45(12):2917-24
7388735
Cancer. 1989 Jan 1;63(1):181-7
2910416
Breast Cancer Res Treat. 1998;51(3):255-65
10068083
Br J Cancer. 1957 Sep;11(3):359-77
13499785
J Clin Oncol. 1999 May;17(5):1442-8
10334529
Lancet. 1999 Sep 11;354(9182):896-900
10489948
Semin Oncol. 2003 Oct;30(5 Suppl 16):4-13
14613021
N Engl J Med. 2002 Dec 19;347(25):1999-2009
12490681
Clin Cancer Res. 2003 Mar;9(3):1039-46
12631604
Cancer. 2004 Dec 1;101(11):2509-15
15495180
J Clin Oncol. 2001 Feb 15;19(4):980-91
11181660
Clin Cancer Res. 1998 Jan;4(1):7-12
9516946
J Clin Oncol. 2001 Jan 15;19(2):329-35
11208823
Cancer Res. 2002 Aug 15;62(16):4617-22
12183417
J Natl Cancer Inst. 2001 Jun 20;93(12):913-20
11416112
J Clin Oncol. 2002 Sep 1;20(17):3628-36
12202663
J Natl Cancer Inst. 2001 Jul 4;93(13):979-89
11438563